Understand the source comparison
GHRP-2 Acetate Science: Comparison of Growth Hormone Secretagogues
The following table compares GHRP-2 acetate to four related growth hormone secretagogues based on receptor affinity, side effect profile, and typical research applications. GHRP-2 Acetate GHS-R1a agonist (pituitary) 100% (baseline) Minimal (15–20% above baseli
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares GHRP-2 acetate to four related growth hormone secretagogues based on receptor affinity, side effect profile, and typical research applications.
- GHRP-2 Acetate
- GHS-R1a agonist (pituitary)
- 100% (baseline)
- Minimal (15–20% above baseline)
- Mild to moderate
- 20–30 minutes
- Best balance of potency and selectivity. Minimal side effects with strong GH output
- GHRP-6
- GHS-R1a agonist (pituitary + hypothalamus)
- 110–120%
- Moderate to high (40–60% elevation)
- Strong
- Higher GH release but significant appetite and cortisol effects limit research utility
- Hexarelin
- 130–150%
- Moderate (25–35% elevation)
- Moderate
- 30–40 minutes
- Strongest GH release but rapid receptor desensitization within 7–10 days
- Ipamorelin
- GHS-R1a agonist (highly selective)
- 60–70%
- Negligible (<5% elevation)
- Minimal
- 120 minutes
- Most selective with fewest side effects. Lower GH output per dose
- MK-677 (Ibutamoren)
- GHS-R1a agonist (oral, non-peptide)
- Sustained elevation vs pulsatile
- Strong (dose-dependent)
- 24+ hours
- Oral bioavailability and sustained release. Disrupts ultradian rhythm, insulin resistance risk
- GHRP-2 acetate occupies the optimal zone for studies prioritizing reproducible pulsatile GH release without the appetite or cortisol complications of GHRP-6 or the desensitization risk of Hexarelin.